MDWD - MediWound reports positive initial data from Phase 2 EscharEx study in chronic hard to heal wounds

MediWound (NASDAQ:MDWD) announces positive initial data from seven of the maximum fifteen patients in its ongoing Phase 2 pharmacology study of EscharEx, the company’s next-generation enzymatic debridement agent under development for chronic and hard-to-heal wounds. Shares up 2.5% premarket at $2.50. Following treatment of seven patients with either diabetic foot ulcers or venous leg ulcers, EscharEx demonstrated safe and effective debridement of lower leg ulcer within a few daily applications. In addition, evaluation of wounds’ tissue samples (biopsies) and fluorescence images, indicated reduction of biofilm and bacterial load following the treatment with EscharEx. The company expects to share the full data set from this study in H1 2022. In two completed phase 2 trials, EscharEx was well-tolerated and demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds with only few daily applications.

For further details see:

MediWound reports positive initial data from Phase 2 EscharEx study in chronic, hard to heal wounds